NEW YORK, Feb 21 – Variagenics said Wednesday it sold its NuCleave genotyping and haplotyping system to the Amsterdam Genomics Center at the University of Amsterdam.

The Amsterdam Genomics Center is Variagenics’ second announced customer for NuCleave. Variagenics launched NuCleave in the fourth quarter of 2000 and placed its first system at Covance, which is using the system for genetic variance determination in clinical trials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.